XGN Exagen Inc.
Stock · NasdaqGM · United States · Healthcare · US30068X1037
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Exagen Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD.
Updated 06 Nov 2026 21:06. Information, not advice.
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 10 Nov 2026 08:00 | -0.17 | — | — | Upcoming |
| 04 Aug 2026 08:00 | -0.17 | -0.11 | +32.6% | Beat |
| 11 May 2026 08:00 | -0.25 | -0.20 | +18.7% | Beat |
| 10 Mar 2026 08:00 | -0.19 | -0.27 | -37.7% | Miss |
| 04 Nov 2025 08:00 | -0.16 | -0.31 | -96.8% | Miss |
| 29 Jul 2025 08:00 | -0.15 | -0.18 | -18.8% | Miss |
| 05 May 2025 08:00 | -0.21 | -0.20 | +3.2% | Beat |
| 11 Mar 2025 08:00 | -0.24 | -0.20 | +16.7% | Beat |
| 12 Nov 2024 08:00 | -0.28 | -0.28 | +1.8% | Beat |
| 05 Aug 2024 08:00 | -0.35 | -0.16 | +54.0% | Beat |
| 13 May 2024 09:00 | -0.35 | -0.19 | +45.7% | Beat |
| 18 Mar 2024 09:00 | -0.43 | -0.31 | +28.3% | Beat |
| 13 Nov 2023 16:00 | -0.49 | -0.31 | +37.1% | Beat |
| 07 Aug 2023 08:00 | -0.49 | -0.28 | +42.9% | Beat |
| 15 May 2023 17:00 | -0.56 | -0.44 | +22.1% | Beat |
| 20 Mar 2023 17:00 | -0.76 | -0.83 | -9.2% | Miss |
| 14 Nov 2022 16:00 | -0.76 | -0.47 | +38.3% | Beat |
| 04 Aug 2022 17:00 | -0.57 | -0.78 | -37.3% | Miss |
| 11 May 2022 17:00 | -0.61 | -0.60 | +1.6% | Beat |
| 22 Mar 2022 16:00 | -0.50 | -0.42 | +15.3% | Beat |
| 10 Nov 2021 17:00 | -0.47 | -0.42 | +11.0% | Beat |
| 09 Aug 2021 17:00 | -0.44 | -0.38 | +13.0% | Beat |
| 11 May 2021 16:00 | -0.48 | -0.48 | +0.4% | In line |
| 16 Mar 2021 16:00 | -0.40 | -0.27 | +32.1% | Beat |
| 10 Nov 2020 17:00 | -0.47 | -0.34 | +28.3% | Beat |
| 28 Jul 2020 07:00 | -0.79 | -0.27 | +66.0% | Beat |
| 11 May 2020 16:00 | -0.56 | -0.44 | +22.1% | Beat |
| 25 Mar 2020 16:00 | -0.37 | -0.27 | +26.4% | Beat |
| 12 Nov 2019 16:00 | -2.40 | -11.29 | -370.4% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 66.6M | +19.7% | -20M | -30.0% | -0.93 | -12.0% | -14.3M |
| 2024 | 55.6M | +5.9% | -15.1M | -27.2% | -0.83 | +38.1% | -13.8M |
| 2023 | 52.5M | +15.3% | -23.7M | -45.1% | -1.34 | +51.6% | -15.3M |
| 2022 | 45.6M | — | -47.4M | -104.0% | -2.77 | — | -36.5M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 05 Apr 2024 | 1.47 | 1.53 | 1.42 | 1.50 | -1.32% | 22,000 | |
| 04 Apr 2024 | 1.58 | 1.60 | 1.42 | 1.52 | -1.94% | 52,200 | |
| 03 Apr 2024 | 1.48 | 1.58 | 1.48 | 1.55 | +2.65% | 20,300 | |
| 02 Apr 2024 | 1.48 | 1.55 | 1.48 | 1.51 | -3.82% | 45,200 | |
| 01 Apr 2024 | 1.62 | 1.64 | 1.43 | 1.57 | -1.26% | 82,800 | |
| 28 Mar 2024 | 1.57 | 1.65 | 1.52 | 1.59 | +1.92% | 26,100 | |
| 27 Mar 2024 | 1.57 | 1.58 | 1.46 | 1.56 | +1.30% | 47,600 | |
| 26 Mar 2024 | 1.47 | 1.56 | 1.44 | 1.54 | +8.45% | 48,200 | |
| 25 Mar 2024 | 1.64 | 1.68 | 1.42 | 1.42 | -11.80% | 81,000 | |
| 22 Mar 2024 | 1.62 | 1.67 | 1.57 | 1.61 | -3.59% | 40,000 | |
| 21 Mar 2024 | 1.64 | 1.88 | 1.56 | 1.67 | +3.73% | 180,100 | |
| 20 Mar 2024 | 1.69 | 1.74 | 1.51 | 1.61 | +4.55% | 99,600 | |
| 19 Mar 2024 | 1.70 | 1.72 | 1.51 | 1.54 | -12.99% | 121,000 | |
| 18 Mar 2024 | 1.91 | 2.05 | 1.75 | 1.77 | +9.26% | 197,700 | |
| 15 Mar 2024 | 1.74 | 1.81 | 1.61 | 1.62 | -5.81% | 74,400 | |
| 14 Mar 2024 | 1.84 | 1.84 | 1.70 | 1.72 | -2.82% | 10,600 | |
| 13 Mar 2024 | 1.83 | 1.90 | 1.75 | 1.77 | -2.21% | 45,600 | |
| 12 Mar 2024 | 1.85 | 1.93 | 1.80 | 1.81 | -2.16% | 32,300 | |
| 11 Mar 2024 | 1.89 | 1.94 | 1.84 | 1.85 | -2.63% | 22,800 | |
| 08 Mar 2024 | 1.91 | 1.97 | 1.90 | 1.90 | -3.06% | 22,000 | |
| 07 Mar 2024 | 1.95 | 1.98 | 1.90 | 1.96 | -0.71% | 5,200 | |
| 06 Mar 2024 | 1.93 | 1.98 | 1.85 | 1.97 | +1.23% | 14,600 | |
| 05 Mar 2024 | 1.93 | 2.01 | 1.88 | 1.95 | +2.63% | 22,300 | |
| 04 Mar 2024 | 2.02 | 2.02 | 1.85 | 1.90 | -5.94% | 48,900 | |
| 01 Mar 2024 | 2.22 | 2.27 | 1.99 | 2.02 | -10.22% | 42,200 |
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
Key data
- Previous close
- 7.60 USD
- Market cap
- 184.1M
- Exchange
- NasdaqGM
- Country
- United States
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 22.5 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 3.2 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.5 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only -3.3× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | -12.36× | Weak | 14.98× |
| Price / book | 11.5× | Weak | 3.87× |
| Price / sales | 1.98× | Good | 3.42× |
| EV / EBITDA | -17.38× | Weak | 13.09× |
| Free cash flow yield | -1.1% | Weak | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 58.6% | Good | 59.2% |
| Operating margin | -8.6% | Weak | 7.8% |
| Net margin | -26.6% | Weak | 3.4% |
| Return on equity | -113.8% | Weak | 5.7% |
| Return on assets | -14.9% | Weak | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 13.5% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 2.26× | Weak | 0.46× |
| Interest cover | -3.26× | Weak | 3.26× |
| Current ratio | 3.19× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow XGN and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.